Latest interview, page-3

Thank you, Rinnekin for posting the Pro active investor interview video.
James has his mojo back with discussion on the release dates of paxalisib trials both interim and final data next month.
He discusses demand from the US sophisticated investors for ADS's - At The Market (ATM) share cash equity issuing facility eloquently, using examples of possible liquidity demand for ADS's - ATM when the KZIA share price is maybe double or triple in value, which could be triggered by new regional drug licence agreements, (similar to the Simcere China licence)
Possible new paxalisib trial next year for rare childhood cancer AT/RT
DIPG - PNOC study recruiting like wildfire with possibility of registration approval with a valuable rare childhood disease voucher attached.
GBM AGILE phase 3 registration data available - 2H CY2023.
And the list goes on and on.

Regards.